brivanib

Overview

Brivanib is a dual inhibitor of VEGFR2 (KDR) and FGFR1. It was investigated as a frontline and TACE-combination agent in hepatocellular carcinoma (HCC) but failed to demonstrate superiority over sorafenib or to improve outcomes when added to TACE.

Evidence in the corpus

• Failed as a frontline HCC agent vs sorafenib: median OS 8.0–8.8 months vs 9.9–10.0 months for sorafenib (HR ~1.12–1.15); cited alongside sunitinib, linifanib, and erlotinib as frontline failures PMID:24798001.
• Brivanib + TACE did not improve TTP or OS vs TACE alone in phase III HCC; cited as a negative TACE-combination result PMID:24798001.

Resistance mechanisms

Cancer types (linked)

• HCC

Sources

This page was processed by entity-page-writer on 2026-05-11.